Why BofA Is Double Downgrading Cerner: 'Not Much Room For Upside'

Cerner Corporation’s CERN long-term growth is likely to be slightly lower than was earlier anticipated, and there is lack of a “possible novel catalyst” to drive share price appreciation, according to BofA Securities.

The Cerner Analyst: Michael Cherny downgraded Cerner from Buy to Underperform and lowered the price target from $82 to $76.

The Cerner Thesis: The company is still among the market leaders across health IT and electronic health records, Cherny said in a Tuesday downgrade note.

Cerner could sustain growth and leverage its installed base to move into more strategic growth areas “over a multiyear period,” the analyst said. 

Additional contributions from the rollout of the company's Veterans Affairs contract should also support double-digit growth, he said.

These catalysts are already well-understood, and the next opportunity for upside is unclear “given the maturity of the traditional core business and the longer-dated potential contribution from the newer growth opportunities,” Cherny said. 

“Additionally, we see CERN’s valuation as not necessarily stretched but also not leaving much room for upside vs. its multi-year average. We do not foresee meaningful stock downside from here but also do not have enough upside to warrant a more constructive stance.”

CERN Price Action: Shares of Cerner were down by 0.94% at $79.46 at last check. 

Cerner headquarters. Photo by Americasroof via Wikimedia

Market News and Data brought to you by Benzinga APIs
Comments
Loading...
Posted In: Analyst ColorDowngradesPrice TargetAnalyst RatingsBofA SecuritiesMichael Cherny
Benzinga simplifies the market for smarter investing

Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.

Join Now: Free!